EUVIMEDEUVIMED entdecken
Open Access

Combined innate immune cell therapy, tumor-specific antibody, and radiation prompt antitumor response in pancreatic cancer models

Md Mahfuzur Rahman iD, Andrea Pennati iD, Tavus Atajanova, Trishna Debnath, Raad H Allawi iD, Ross O Meyers iD, Tracy J Berg iD, Zafer Gurel iD, Nataliya V Uboha, Michael F Bassetti iD, Lu Mao iD, Paul M Sondel iD und 5 weitere

Science Advances · 05.12.2025 · 11 (49)

DOI: 10.1126/sciadv.adx2984 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, erschienen am 05.12.2025. Verfasst von Md Mahfuzur Rahman und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Immunity, Innate, Immunotherapy, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NHLBI NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma (PDAC) is generally resistant to conventional immunotherapies due to its immunosuppressive tumor microenvironment (TME). We combine an innate cell–enriched product activated by interleukin-2 (IL-2) and zoledronic acid (ZA) (ICP IL2ZA ) with low-dose radiotherapy (RT) and monoclonal antibodies (mAbs) to overcome this immunosuppressive TME. ICP IL2ZA is composed of natural killer (NK) cell– and monocyte-enriched immune cells, activated ex vivo with IL-2 and ZA. ICP IL2ZA with RT and mAbs promotes antibody-dependent cellular cytotoxicity and phagocytosis against PDAC. In murine models of PDAC, RT and mAb combined with ICP IL2ZA derived from either murine or healthy human donors controlled tumor growth. RT amplifies ICP IL2ZA effectiveness by inducing NKG2D ligands on tumor cells, facilitating immune infiltration that leads to tumor growth control and extends survival without apparent toxicity. These results suggest that ICP IL2ZA can overcome limitations of traditional therapies by augmenting antitumor capabilities of endogenous immune cells, highlighting a promising autologous strategy for PDAC and other immunologically “cold” tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsImmunity, InnateImmunotherapyCarcinoma, Pancreatic DuctalAntibodies, MonoclonalAnimalsHumansMiceCell Line, TumorTumor MicroenvironmentKiller Cells, NaturalDisease Models, AnimalZoledronic AcidInterleukin-2Combined Modality Therapy

Substanzen

Antibodies, MonoclonalZoledronic AcidInterleukin-2

Autor:innen und Institutionen

  • Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
  • Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
  • Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
  • Department of Biostatistics and Medical Informatics, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
  • Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.

ORCID-Profile: Md Mahfuzur Rahman, Andrea Pennati, Raad H Allawi, Ross O Meyers, Tracy J Berg, Zafer Gurel, Michael F Bassetti, Lu Mao, Paul M Sondel, Randall J Kimple, Christian M Capitini, Quaovi H Sodji, Jacques Galipeau, Zachary S Morris

Förderung

  • NCI NIH HHS
  • NHLBI NIH HHS
  • National Institutes of Health
  • Midwest Athletes Against Childhood Cancer
  • St. Baldrick’s Foundation Empowering Pediatric Immunotherapy for Childhood Cancers

Zitieren

APA

Rahman, M. M., Pennati, A., Atajanova, T., Debnath, T., Allawi, R. H., Meyers, R. O., Berg, T. J., Gurel, Z., Uboha, N. V., Bassetti, M. F., Mao, L., Sondel, P. M., Kimple, R. J., Capitini, C. M., Sodji, Q. H., Galipeau, J., & Morris, Z. S. (2025). Combined innate immune cell therapy, tumor-specific antibody, and radiation prompt antitumor response in pancreatic cancer models. Science Advances, 11(49). https://doi.org/10.1126/sciadv.adx2984

Vancouver

Rahman MM, Pennati A, Atajanova T, Debnath T, Allawi RH, Meyers RO, et al. Combined innate immune cell therapy, tumor-specific antibody, and radiation prompt antitumor response in pancreatic cancer models. Science Advances. 2025;11(49). doi:10.1126/sciadv.adx2984

BibTeX
@article{Rahman2025,
  author = {Rahman, Md Mahfuzur and Pennati, Andrea and Atajanova, Tavus and Debnath, Trishna and Allawi, Raad H and Meyers, Ross O and Berg, Tracy J and Gurel, Zafer and Uboha, Nataliya V and Bassetti, Michael F and Mao, Lu and Sondel, Paul M and Kimple, Randall J and Capitini, Christian M and Sodji, Quaovi H and Galipeau, Jacques and Morris, Zachary S},
  title = {Combined innate immune cell therapy, tumor-specific antibody, and radiation prompt antitumor response in pancreatic cancer models},
  journal = {Science Advances},
  year = {2025},
  volume = {11},
  number = {49},
  doi = {10.1126/sciadv.adx2984}
}
Kostenlos starten →